EMCURE PHARMACEUTICALS L (EMCURE)

NSE: ₹1,745.20
BSE: ₹1,744.70
Stock Performance
Corporate Announcements
No recent announcements available.

Quarterly Financials

Consolidated Standalone
Particulars Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 970.29 1,104.63 1,028.81 1,278.19 1,096.57 1,260.60 1,418.31 1,467.70
YOY Revenue Growth % - - - - 13.01% 14.12% 37.86% 14.83%
Other Income 32.51 54.93 19.41 22.40 21.52 22.75 138.30 26.94
Total Income 1,002.80 1,159.56 1,048.22 1,300.58 1,118.10 1,283.36 1,556.61 1,494.64
Total Expenses + 947.75 1,040.21 980.97 1,114.53 948.93 1,125.47 1,213.09 1,195.96
Cost of Materials Consumed 266.07 325.99 350.91 365.01 354.63 374.18 368.53 377.85
Employee Benefit Expense 195.09 191.12 196.01 198.16 210.42 202.68 205.65 202.37
Other Expenses 243.91 256.56 229.86 227.41 249.97 266.76 296.77 245.00
Operating Profit 22.54 64.43 47.84 163.66 147.65 135.14 205.22 271.75
OPM % 2.3% 5.8% 4.7% 12.8% 13.5% 10.7% 14.5% 18.5%
Profit Before Tax + 55.05 119.36 67.25 186.05 165.67 157.89 314.37 306.27
Tax Expense 14.60 32.44 17.05 46.50 42.88 40.27 55.51 72.57
Tax % 26.5% 27.2% 25.3% 25% 25.9% 25.5% 17.7% 23.7%
Profit After Tax 40.45 86.92 50.20 139.56 122.79 117.62 258.85 233.70
EPS (Basic) 2.23 4.62 2.65 7.37 6.48 6.21 13.65 12.33

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025
Revenue from Operations 5,243.19 4,381.92
YOY Revenue Growth % 19.65% -
Other Income 209.52 118.81
Total Income 5,452.70 4,500.73
Total Expenses + 4,483.44 4,073.02
Cost of Materials Consumed 1,475.18 1,307.98
Employee Benefit Expense 821.12 782.31
Other Expenses 1,058.50 945.37
Operating Profit 759.75 308.90
OPM % 14.5% 7%
Profit Before Exceptional 969.26 427.71
Exceptional Items -25.07 0.00
Profit Before Tax + 944.19 427.71
Tax Expense 211.23 110.58
Tax % 22.4% 25.9%
Profit After Tax 732.96 317.13
EPS (Basic) 38.67 16.95

Balance Sheet

Particulars Mar 2026 Mar 2025
ASSETS
Non-Current Assets + 3,872.98 2,908.86
Property, Plant & Equipment 1,444.71 1,459.85
Capital Work in Progress 110.24 92.83
Non-Current Investments 1,424.30 677.65
Goodwill 0.00 0.00
Other Intangible Assets 22.64 26.22
Current Assets + 3,041.07 2,507.25
Inventories 1,206.70 1,038.18
Trade Receivables 1,534.87 1,190.56
Cash and Cash Equivalents 11.25 8.49
Current Investments 0.00 0.00
LIABILITIES & EQUITY
Total Equity 3,710.60 3,024.36
Equity Share Capital 189.59 189.48
Other Equity 3,521.01 2,834.88
Non-Current Liabilities 936.03 672.59
Current Liabilities 2,267.42 1,719.16
Total Liabilities 3,203.45 2,391.75

Cash Flow Statement

Particulars Mar 2026 Mar 2025
Cash from Operating Activities 423.56 558.29
Cash from Investing Activities -948.10 -435.61
Cash from Financing Activities 525.76 -49.25
Net Increase/Decrease in Cash 2.51 71.38